Unknown

Dataset Information

0

Long noncoding RNA FOXD2-AS1 enhances chemotherapeutic resistance of laryngeal squamous cell carcinoma via STAT3 activation.


ABSTRACT: Laryngeal squamous cell carcinoma (LSCC) is a common head and neck cancer. Despite recently improved management of LSCC, chemotherapy resistance of patients remains a challenge. In this study, we identified that long noncoding RNA FOXD2-AS1 regulates LSCC therapeutic resistance by augmenting LSCC stemness. LSCC chemotherapy-resistant patients showed increased FOXD2-AS1 expression compared with that in chemotherapy-sensitive patients, which predicted poor prognosis. Gain- or loss-of-function experiments showed that upregulated FOXD2-AS1 maintained cancer stemness, reducing the response to chemotherapy, while FOXD2-AS1 downregulation had the opposite effects. FOXD2-AS1 acted as a scaffold for STAT3 and PRMT5, promoting STAT3 transcriptional activity, which is essential to maintain cancer stemness and promote chemotherapeutic resistance. Interfering with FOXD2-AS1 using short hairpin RNA rescued LSCC's chemotherapeutic sensitivity. Thus, FOXD2-AS1 promotes LSCC chemotherapeutic resistance and is an upstream activator of STAT3, making FOXD2-AS1 a potential therapeutic target to improve the chemotherapy effect in LSCC patients.

SUBMITTER: Li R 

PROVIDER: S-EPMC6971019 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Long noncoding RNA FOXD2-AS1 enhances chemotherapeutic resistance of laryngeal squamous cell carcinoma via STAT3 activation.

Li Rui R   Chen Shuwei S   Zhan Jiandong J   Li Xinghua X   Liu Wenlin W   Sheng Xiaoli X   Lu Zhongming Z   Zhong Rong R   Chen Liangsi L   Luo Xiaoning X   Hu Yameng Y   Ouyang Ying Y   Liu Tao T   Zhang Quan Q   Zhang Siyi S  

Cell death & disease 20200120 1


Laryngeal squamous cell carcinoma (LSCC) is a common head and neck cancer. Despite recently improved management of LSCC, chemotherapy resistance of patients remains a challenge. In this study, we identified that long noncoding RNA FOXD2-AS1 regulates LSCC therapeutic resistance by augmenting LSCC stemness. LSCC chemotherapy-resistant patients showed increased FOXD2-AS1 expression compared with that in chemotherapy-sensitive patients, which predicted poor prognosis. Gain- or loss-of-function expe  ...[more]

Similar Datasets

| S-EPMC10189999 | biostudies-literature
| S-EPMC7819824 | biostudies-literature
| S-EPMC7005577 | biostudies-literature
| S-EPMC7263938 | biostudies-literature
2016-12-29 | GSE84957 | GEO
2016-07-26 | E-GEOD-84807 | biostudies-arrayexpress
| S-EPMC5199101 | biostudies-literature
| S-EPMC7303144 | biostudies-literature
| S-EPMC6756574 | biostudies-literature
| S-EPMC7266282 | biostudies-literature